Veeva Systems earnings release, August 26, 2026
Veeva Announces Fiscal 2027 Second Quarter Results
Total Revenues of $928.0M, up 18% Year Over Year
Subscription Revenues of $766.8M, up 16% Year Over Year
PLEASANTON, CA — August 26, 2026 — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.
“AI is opening up the next big chapter for Veeva and life sciences,” said CEO Peter Gassner. “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients.”
Fiscal 2027 Second Quarter Results:
• Revenues
: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year.
• Operating Income and Non-GAAP Operating Income
:
(1)
Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year.
• Net Income and Non-GAAP Net Income
:
(1)
Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year.
• Net Income per Share and Non-GAAP Net Income per Share
:
(1)
For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.
“Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board,” said CFO Brian Van Wagener. “We continue to execute well across the business while also accelerating innovation and progress in new growth areas.”
Recent Highlights:
• Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry's fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter.
• Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development.
• Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training.
Financial Outlook:
Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:
• Total revenues between $932 and $935 million.
• Non-GAAP operating income between $417 and $420 million.
(2)
• Non-GAAP fully diluted net income per share between $2.33 and $2.34.
(2)
Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:
• Total revenues between $3,682 and $3,687 million.
• Non-GAAP operating income of about $1,640 million.
(2)
• Non-GAAP fully diluted net income per share of approximately $9.21.
(2)
Conference Call Information
Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva's investor relations website.
___________
(1)
This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled
“
Non-GAAP Financial Measures” and the tables entitled
“
Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.
(2)
Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.
About Veeva Systems... (truncated)ng customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Financial statements
Income Statement
Three months ended July 31, — (Unaudited)
| Three months ended July 31, – 2026 | Three months ended July 31, – 2025 | Six months ended July 31, – 2026 | Six months ended July 31, – 2025 | ||
|---|---|---|---|---|---|
| Revenues: | Subscription(3) | 766,764 | 659,183 | 1,496,939 | 1,293,951 |
| Revenues: | Professional services and other(4) | 161,199 | 129,898 | 313,972 | 254,173 |
| Revenues: | Total revenues | 927,963 | 789,081 | 1,810,911 | 1,548,124 |
| Cost of revenues(5): | Cost of subscription | 105,677 | 93,830 | 204,780 | 172,176 |
| Cost of revenues(5): | Cost of professional services and other | 126,335 | 101,423 | 248,156 | 196,901 |
| Cost of revenues(5): | Total cost of revenues | 232,012 | 195,253 | 452,936 | 369,077 |
| Cost of revenues(5): | Gross profit | 695,951 | 593,828 | 1,357,975 | 1,179,047 |
| Operating expenses(5): | Research and development | 222,918 | 192,677 | 431,241 | 376,710 |
| Operating expenses(5): | Sales and marketing | 126,701 | 109,439 | 237,818 | 208,067 |
| Operating expenses(5): | General and administrative | 71,314 | 95,804 | 140,786 | 164,630 |
| Operating expenses(5): | Total operating expenses | 420,933 | 397,920 | 809,845 | 749,407 |
| Operating expenses(5): | Operating income | 275,018 | 195,908 | 548,130 | 429,640 |
| Operating expenses(5): | Other income, net | 74,512 | 69,456 | 148,930 | 134,545 |
| Operating expenses(5): | Income before income taxes | 349,530 | 265,364 | 697,060 | 564,185 |
| Operating expenses(5): | Income tax provision | 76,101 | 65,055 | 162,695 | 135,686 |
| Operating expenses(5): | Net income | 273,429 | 200,309 | 534,365 | 428,499 |
| Net income per share: | Basic | 1.68 | 1.23 | 3.28 | 2.63 |
| Net income per share: | Diluted | 1.66 | 1.19 | 3.22 | 2.56 |
| Weighted-average shares used to compute net income per share: | Basic | 162,344 | 163,496 | 162,836 | 163,129 |
| Weighted-average shares used to compute net income per share: | Diluted | 165,057 | 167,685 | 166,072 | 167,272 |
| Other comprehensive income: | Net change in unrealized (loss) gain on available-for-sale investments | -26,490 | -11,300 | -53,941 | 6,067 |
| Other comprehensive income: | Net change in cumulative foreign currency translation gain (loss) | 135 | 390 | -366 | 352 |
| Other comprehensive income: | Comprehensive income | 247,074 | 189,399 | 480,058 | 434,918 |
| (3) Includes subscription revenues from the following product areas: | Veeva Commercial Solutions | 347,389 | 307,523 | 685,255 | 612,934 |
| (3) Includes subscription revenues from the following product areas: | Veeva R&D and Quality Solutions | 419,375 | 351,660 | 811,684 | 681,017 |
| (3) Includes subscription revenues from the following product areas: | Total subscription | 766,764 | 659,183 | 1,496,939 | 1,293,951 |
| (4) Includes professional services and other revenues from the following product areas: | Veeva Commercial Solutions | 59,742 | 47,703 | 117,315 | 94,270 |
| (4) Includes professional services and other revenues from the following product areas: | Veeva R&D and Quality Solutions | 101,457 | 82,195 | 196,657 | 159,903 |
| (4) Includes professional services and other revenues from the following product areas: | Total professional services and other | 161,199 | 129,898 | 313,972 | 254,173 |
| Cost of revenues: | Cost of subscription | 2,224 | 1,941 | 3,985 | 3,656 |
| Cost of revenues: | Cost of professional services and other | 15,939 | 14,804 | 30,090 | 27,573 |
| Cost of revenues: | Research and development | 62,220 | 53,388 | 113,783 | 101,337 |
| Cost of revenues: | Sales and marketing | 27,886 | 25,392 | 52,480 | 47,713 |
| Cost of revenues: | General and administrative | 28,534 | 26,441 | 55,724 | 53,897 |
| Cost of revenues: | Total stock-based compensation | 136,803 | 121,966 | 256,062 | 234,176 |
Income Statement
Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-G — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
| Three months ended July 31, – 2026 | 2026 | Three months ended July 31, – 2026 | 2026 | 2025 | Three months ended July 31, – 2025 | 2025 | Six months ended July 31, – 2026 | 2026 | Six months ended July 31, – 2026 | 2026 | 2025 | Six months ended July 31, – 2025 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net cash provided by operating activities on a GAAP basis | 238,709 | 238,433 | 1,365,825 | 1,115,591 | ||||||||||
| Excess tax (benefit) deficiency from employee stock plans | -3,268 | -13,031 | 824 | -15,610 | ||||||||||
| Net cash provided by operating activities on a non-GAAP basis | 235,441 | 225,402 | 1,366,649 | 1,099,981 | ||||||||||
| Net cash used in investing activities on a GAAP basis | -63,540 | -389,272 | -452,251 | -441,379 | ||||||||||
| Net cash (used in) provided by financing activities on a GAAP basis | -259,308 | 115,689 | -521,834 | 136,069 | ||||||||||
| Reconciliation of Financial Measures (GAAP basis to non-GAAP basis) | Three months ended July 31, | Six months ended July 31, | ||||||||||||
| Cost of subscription revenues on a GAAP basis | 105,677 | 93,830 | 204,780 | 172,176 | ||||||||||
| Stock-based compensation expense | -2,224 | -1,941 | -3,985 | -3,656 | ||||||||||
| Amortization of purchased intangibles | -1,072 | -1,046 | -1,746 | -2,058 | ||||||||||
| Cost of subscription revenues on a non-GAAP basis | 102,381 | 90,843 | 199,049 | 166,462 | ||||||||||
| Gross margin on subscription revenues on a GAAP basis | 86.2 | 85.8 | 86.3 | 86.7 | ||||||||||
| Stock-based compensation expense | 0.3 | 0.3 | 0.3 | 0.3 | ||||||||||
| Amortization of purchased intangibles | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||
| Gross margin on subscription revenues on a non-GAAP basis | 86.6 | 86.2 | 86.7 | 87.1 | ||||||||||
| Cost of professional services and other revenues on a GAAP basis | 126,335 | 101,423 | 248,156 | 196,901 |
Income Statement
Three months ended July 31, — (Unaudited)
| Three months ended July 31, – 2026 | Three months ended July 31, – 2025 | Six months ended July 31, – 2026 | Six months ended July 31, – 2025 | |
|---|---|---|---|---|
| Sales and marketing expense on a GAAP basis | 126,701 | 109,439 | 237,818 | 208,067 |
| Stock-based compensation expense | -27,886 | -25,392 | -52,480 | -47,713 |
| Amortization of purchased intangibles | -2,720 | -2,890 | -5,051 | -5,685 |
| Sales and marketing expense on a non-GAAP basis | 96,095 | 81,157 | 180,287 | 154,669 |
| General and administrative expense on a GAAP basis | 71,314 | 95,804 | 140,786 | 164,630 |
| Stock-based compensation expense | -28,534 | -26,441 | -55,724 | -53,897 |
| Litigation settlement-related charges | -30,627 | -30,627 | ||
| General and administrative expense on a non-GAAP basis | 42,780 | 38,736 | 85,062 | 80,106 |
| Operating expense on a GAAP basis | 420,933 | 397,920 | 809,845 | 749,407 |
| Stock-based compensation expense | -118,640 | -105,221 | -221,987 | -202,947 |
| Amortization of purchased intangibles | -2,990 | -2,890 | -5,321 | -5,685 |
| Litigation settlement-related charges | -30,627 | -30,627 | ||
| Operating expense on a non-GAAP basis | 299,303 | 259,182 | 582,537 | 510,148 |
| Operating income on a GAAP basis | 275,018 | 195,908 | 548,130 | 429,640 |
| Stock-based compensation expense | 136,803 | 121,966 | 256,062 | 234,176 |
| Amortization of purchased intangibles | 4,062 | 4,075 | 7,067 | 8,016 |
| Litigation settlement-related charges | 30,627 | 30,627 | ||
| Operating income on a non-GAAP basis | 415,883 | 352,576 | 811,259 | 702,459 |
| Operating margin on a GAAP basis | 29.6 | 24.8 | 30.3 | 27.8 |
| Stock-based compensation expense | 14.7 | 15.5 | 14.1 | 15.1 |
| Amortization of purchased intangibles | 0.5 | 0.5 | 0.4 | 0.5 |
| Litigation settlement-related charges | 3.9 | 2 | ||
| Operating margin on a non-GAAP basis | 44.8 | 44.7 | 44.8 | 45.4 |
| Net income on a GAAP basis | 273,429 | 200,309 | 534,365 | 428,499 |
| Stock-based compensation expense | 136,803 | 121,966 | 256,062 | 234,176 |
| Amortization of purchased intangibles | 4,062 | 4,075 | 7,067 | 8,016 |
| Litigation settlement-related charges | 30,627 | 30,627 | ||
| Income tax effect on non-GAAP adjustments(6) | -26,882 | -23,572 | -38,945 | -40,085 |
| Net income on a non-GAAP basis | 387,412 | 333,406 | 758,549 | 661,234 |
| Diluted net income per share on a GAAP basis | 1.66 | 1.19 | 3.22 | 2.56 |
| Stock-based compensation expense | 0.83 | 0.73 | 1.54 | 1.4 |
| Amortization of purchased intangibles | 0.02 | 0.02 | 0.04 | 0.05 |
| Litigation settlement-related charges | 0.18 | 0.18 | ||
| Income tax effect on non-GAAP adjustments(6) | -0.16 | -0.13 | -0.23 | -0.24 |
| Diluted net income per share on a non-GAAP basis | 2.35 | 1.99 | 4.57 | 3.95 |
Balance Sheet
(Unaudited)
| July 31, 2026 | January 31, 2026 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 1,812,012 | 1,421,233 |
| Current assets: | Short-term investments | 5,430,935 | 5,139,581 |
| Current assets: | Accounts receivable, net | 496,677 | 1,259,737 |
| Current assets: | Unbilled accounts receivable | 68,970 | 50,609 |
| Current assets: | Prepaid expenses and other current assets | 137,633 | 126,470 |
| Current assets: | Total current assets | 7,946,227 | 7,997,630 |
| Current assets: | Property and equipment, net | 79,483 | 70,261 |
| Current assets: | Deferred costs, net | 27,835 | 29,961 |
| Current assets: | Lease right-of-use assets | 129,320 | 75,626 |
| Current assets: | Goodwill | 492,991 | 439,877 |
| Current assets: | Intangible assets, net | 55,647 | 30,314 |
| Current assets: | Deferred income taxes | 268,250 | 273,417 |
| Current assets: | Other long-term assets | 60,470 | 62,257 |
| Current assets: | Total assets | 9,060,223 | 8,979,343 |
| Current liabilities: | Accounts payable | 35,977 | 37,644 |
| Current liabilities: | Accrued compensation and benefits | 42,188 | 45,857 |
| Current liabilities: | Accrued expenses and other current liabilities | 49,634 | 45,885 |
| Current liabilities: | Income tax payable | 3,018 | 6,698 |
| Current liabilities: | Deferred revenue | 1,310,498 | 1,488,819 |
Cash Flow
Six months ended July 31, — (Unaudited)
| Six months ended July 31, – 2026 | 2025 | ||
|---|---|---|---|
| Cash flows from operating activities | Net income | 534,365 | 428,499 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 22,458 | 19,948 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Reduction of lease right-of-use assets | 7,038 | 6,316 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Accretion of discount on short-term investments | -2,841 | -4,535 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation | 256,062 | 234,176 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of deferred costs | 9,805 | 8,205 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 26,529 | 31,699 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Other, net | -1,127 | -1,414 |
| Changes in operating assets and liabilities: | Accounts receivable | 768,314 | 593,032 |
| Changes in operating assets and liabilities: | Unbilled accounts receivable | -18,361 | -9,587 |
| Changes in operating assets and liabilities: | Deferred costs | -7,679 | -7,721 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current and long-term assets | -21,394 | -21,232 |
| Changes in operating assets and liabilities: | Accounts payable | -652 | 3,361 |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | -1,578 | 23,763 |
| Changes in operating assets and liabilities: | Income tax payable | -3,945 | -5,362 |
| Changes in operating assets and liabilities: | Deferred revenue | -200,001 | -180,888 |
| Changes in operating assets and liabilities: | Lease liabilities | -4,426 | -5,300 |
| Changes in operating assets and liabilities: | Other long-term liabilities | 3,258 | 2,631 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 1,365,825 | 1,115,591 |
| Cash flows from investing activities | Purchases of short-term investments | -1,706,632 | -1,452,857 |
| Cash flows from investing activities | Maturities and sales of short-term investments | 1,345,987 | 1,023,691 |
| Cash flows from investing activities | Long-term assets | -9,773 | -12,213 |
| Cash flows from investing activities | Acquisitions, net of cash acquired | -81,833 | |
| Cash flows from investing activities | Net cash used in investing activities | -452,251 | -441,379 |
| Cash flows from financing activities | Proceeds from exercise of common stock options | 17,143 | 182,297 |
| Cash flows from financing activities | Repurchases of common stock | -472,673 | |
| Cash flows from financing activities | Taxes paid related to net share settlement of equity awards | -66,304 | -46,228 |
| Cash flows from financing activities | Net cash (used in) provided by financing activities | -521,834 | 136,069 |
| Cash flows from financing activities | Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -831 | 1,365 |
| Cash flows from financing activities | Net change in cash, cash equivalents, and restricted cash | 390,909 | 811,646 |
| Cash flows from financing activities | Cash, cash equivalents, and restricted cash at beginning of period | 1,423,412 | 1,120,963 |
| Cash flows from financing activities | Cash, cash equivalents, and restricted cash at end of period | 1,814,321 | 1,932,609 |
| Supplemental disclosures of other cash flow information: | Excess tax (deficiency) benefit from employee stock plans | -824 | 15,610 |
Full release
Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance.
There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 33 and 34 in our filing on Form 10-Q for the period ended
April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.
###